Antiviral Drugs - Mexico | Statista Market Forecast

In Mexico, the revenue in the Antiviral Drugs market is estimated to reach US$288.50m by the year 2024.
It is anticipated that the revenue will display an annual growth rate of 1.53% from 2024 to 2029, leading to a market volume of US$311.30m by 2029.
When compared on a global scale, United States is expected to generate the highest revenue, amounting to US$30.64bn in 2024.
Mexico is experiencing a surge in demand for antiviral drugs due to the increasing prevalence of viral diseases in the country.

Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

HIV
Hepatitis B and hepatitis C
Ebola
COVID-19

Vaccines
Antibiotics
Immunosuppressants
In vitro diagnostics and rapid tests

The demand for Antiviral Drugs in Mexico has been on the rise in recent years.

Customer preferences: Mexican customers are increasingly demanding Antiviral Drugs due to the high incidence of viral diseases in the country. The COVID-19 pandemic has also contributed to the growth of the Antiviral Drugs market in Mexico.

Trends in the market: The Antiviral Drugs market in Mexico is expected to grow at a steady pace due to the increasing prevalence of viral diseases. The market is dominated by multinational pharmaceutical companies that offer a wide range of Antiviral Drugs. However, there is also a growing trend towards the use of generic Antiviral Drugs in Mexico, which are more affordable for the local population.

Local special circumstances: Mexico has a high incidence of viral diseases such as influenza, dengue fever, and chikungunya. The country also has a large population that is vulnerable to viral infections, including the elderly and people with compromised immune systems. The COVID-19 pandemic has further highlighted the need for Antiviral Drugs in Mexico.

Underlying macroeconomic factors: The Antiviral Drugs market in Mexico is driven by several macroeconomic factors, including the country's growing population, increasing healthcare expenditure, and rising disposable income. Mexico is also a major producer of pharmaceuticals and has a well-developed healthcare infrastructure, which supports the growth of the Antiviral Drugs market. However, the market is also subject to regulatory challenges, including price controls and intellectual property rights issues.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.